Marta Mercado-Fernandez

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Journal: Leukemia

Published: August 06, 2015

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Journal: Leukemia

Published: May 21, 2015

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Journal: Leukemia

Published: July 14, 2014

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.

Journal: Leukemia

Published: December 25, 2013

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Journal: Haematologica

Published: July 09, 2013

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Journal: British journal of haematology

Published: April 23, 2013

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.

Journal: British journal of haematology

Published: October 30, 2012

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.

Journal: Leukemia

Published: October 17, 2012

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Journal: PloS one

Published: April 13, 2012

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Journal: Leukemia

Published: March 21, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026